260 related articles for article (PubMed ID: 15272853)
21. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
[TBL] [Abstract][Full Text] [Related]
22. Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors.
Plewe MB; Butler SL; Dress KR; Hu Q; Johnson TW; Kuehler JE; Kuki A; Lam H; Liu W; Nowlin D; Peng Q; Rahavendran SV; Tanis SP; Tran KT; Wang H; Yang A; Zhang J
J Med Chem; 2009 Nov; 52(22):7211-9. PubMed ID: 19873974
[TBL] [Abstract][Full Text] [Related]
23. Development of a receptor model for efficient in silico screening of HIV-1 integrase inhibitors.
Quevedo MA; Ribone SR; Briñón MC; Dehaen W
J Mol Graph Model; 2014 Jul; 52():82-90. PubMed ID: 25023663
[TBL] [Abstract][Full Text] [Related]
24. Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.
Barreca ML; Ortuso F; Iraci N; De Luca L; Alcaro S; Chimirri A
Biochem Biophys Res Commun; 2007 Nov; 363(3):554-60. PubMed ID: 17889829
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of novel indole beta-diketo acid derivatives as HIV-1 integrase inhibitors.
Sechi M; Derudas M; Dallocchio R; Dessì A; Bacchi A; Sannia L; Carta F; Palomba M; Ragab O; Chan C; Shoemaker R; Sei S; Dayam R; Neamati N
J Med Chem; 2004 Oct; 47(21):5298-310. PubMed ID: 15456274
[TBL] [Abstract][Full Text] [Related]
26. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
27. Ethyl malonate amides: a diketo acid offspring fragment for HIV integrase inhibition.
Serafin K; Mazur P; Bak A; Laine E; Tchertanov L; Mouscadet JF; Polanski J
Bioorg Med Chem; 2011 Aug; 19(16):5000-5. PubMed ID: 21767953
[TBL] [Abstract][Full Text] [Related]
28. A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.
De Luca L; Barreca ML; Ferro S; Iraci N; Michiels M; Christ F; Debyser Z; Witvrouw M; Chimirri A
Bioorg Med Chem Lett; 2008 May; 18(9):2891-5. PubMed ID: 18417342
[TBL] [Abstract][Full Text] [Related]
29. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
30. From ligand to complexes. Part 2. Remarks on human immunodeficiency virus type 1 integrase inhibition by beta-diketo acid metal complexes.
Bacchi A; Biemmi M; Carcelli M; Carta F; Compari C; Fisicaro E; Rogolino D; Sechi M; Sippel M; Sotriffer CA; Sanchez TW; Neamati N
J Med Chem; 2008 Nov; 51(22):7253-64. PubMed ID: 18983138
[TBL] [Abstract][Full Text] [Related]
31. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore.
Deng J; Sanchez T; Al-Mawsawi LQ; Dayam R; Yunes RA; Garofalo A; Bolger MB; Neamati N
Bioorg Med Chem; 2007 Jul; 15(14):4985-5002. PubMed ID: 17502148
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 integrase inhibitors: 2003-2004 update.
Dayam R; Deng J; Neamati N
Med Res Rev; 2006 May; 26(3):271-309. PubMed ID: 16496343
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors.
Mustata GI; Brigo A; Briggs JM
Bioorg Med Chem Lett; 2004 Mar; 14(6):1447-54. PubMed ID: 15006380
[TBL] [Abstract][Full Text] [Related]
34. De novo design and synthesis of HIV-1 integrase inhibitors.
Makhija MT; Kasliwal RT; Kulkarni VM; Neamati N
Bioorg Med Chem; 2004 May; 12(9):2317-33. PubMed ID: 15080929
[TBL] [Abstract][Full Text] [Related]
35. Molecular dynamics simulations of the HIV-1 integrase dimerization interface: guidelines for the design of a novel class of integrase inhibitors.
Sippel M; Sotriffer CA
J Chem Inf Model; 2010 Apr; 50(4):604-14. PubMed ID: 20230013
[TBL] [Abstract][Full Text] [Related]
36. Integrase inhibitors for the treatment of HIV infection.
Pace P; Rowley M
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
[TBL] [Abstract][Full Text] [Related]
37. Consideration of molecular weight during compound selection in virtual target-based database screening.
Pan Y; Huang N; Cho S; MacKerell AD
J Chem Inf Comput Sci; 2003; 43(1):267-72. PubMed ID: 12546562
[TBL] [Abstract][Full Text] [Related]
38. Novel technologies for virtual screening.
Lengauer T; Lemmen C; Rarey M; Zimmermann M
Drug Discov Today; 2004 Jan; 9(1):27-34. PubMed ID: 14761803
[TBL] [Abstract][Full Text] [Related]
39. Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.
Loizidou EZ; Zeinalipour-Yazdi CD; Christofides T; Kostrikis LG
Bioorg Med Chem; 2009 Jul; 17(13):4806-18. PubMed ID: 19450984
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles.
Middleton T; Lim HB; Montgomery D; Rockway T; Tang H; Cheng X; Lu L; Mo H; Kohlbrenner WE; Molla A; Kati WM
Antiviral Res; 2004 Oct; 64(1):35-45. PubMed ID: 15451177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
